Abstract
Objective. The aim of this study was to evaluate the prognostic value of the model for end-stage liver disease (MELD) and its modified forms, and to compare these scoring systems with other staging systems for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). Material and methods. A total of 325 patients who underwent TACE for the initial treatment of HCC between January 2000 and May 2007 were enrolled in the study. Before TACE was carried out, MELD, MELD-Na, Child-Pugh score, Okuda stage, CLIP score, JIS score, BCLC stage, and UICC stage were checked. After one month, δMELD and δMELD-Na were calculated. Results. Mean MELD/MELD-Na/δMELD/δMELD-Na scores were 7.5±3.7, 8.0±4.7, -0.2±3.5 and 0.04±4.5, respectively. MELD (p=0.009) and MELD-Na (p=0.017) significantly correlated with survival, but δMELD and δMELD-Na did not (p >0.05). The Child-Pugh score and other staging systems correlated significantly with survival (p <0.05). The AUROC values for 3, 12, and 36 months' survival were 0.633, 0.545, and 0.615 for MELD; 0.655, 0.555, and 0.612 for MELD-Na; 0.639, 0.616, and 0.691 for Child-Pugh score; 0.714, 0.662, and 0.717 for the Okuda score; 0.837, 0.86, and 0.792 for the CLIP score; 0.859, 0.814, and 0.808 for the JIS score; 0.846, 0.833, and 0.749 for BCLC stage; and 0.878, 0.812, and 0.735 for UICC stage, respectively. Conclusions. MELD and MELD-Na showed good correlations with survival, especially for patients with early-stage disease. However, these were not superior to those of other staging systems or Child-Pugh score. These parameters should only be used as supportive data.
| Original language | English |
|---|---|
| Pages (from-to) | 346-357 |
| Number of pages | 12 |
| Journal | Scandinavian Journal of Gastroenterology |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2009 Mar 1 |
Fingerprint
Keywords
- HCC
- MELD
- Survival rate
- TACE
ASJC Scopus subject areas
- Gastroenterology
Cite this
Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. / Kim, Jeong Han; Kim, Ji Hoon; Choi, Jong Hwan; Kim, Chung Ho; Jung, Young Kul; Yim, Hyung Joon; Yeon, Jong Eun; Park, Jong Jae; Kim, Jae Seon; Bak, Young-Tae; Byun, Kwan Soo.
In: Scandinavian Journal of Gastroenterology, Vol. 44, No. 3, 01.03.2009, p. 346-357.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
AU - Kim, Jeong Han
AU - Kim, Ji Hoon
AU - Choi, Jong Hwan
AU - Kim, Chung Ho
AU - Jung, Young Kul
AU - Yim, Hyung Joon
AU - Yeon, Jong Eun
AU - Park, Jong Jae
AU - Kim, Jae Seon
AU - Bak, Young-Tae
AU - Byun, Kwan Soo
PY - 2009/3/1
Y1 - 2009/3/1
N2 - Objective. The aim of this study was to evaluate the prognostic value of the model for end-stage liver disease (MELD) and its modified forms, and to compare these scoring systems with other staging systems for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). Material and methods. A total of 325 patients who underwent TACE for the initial treatment of HCC between January 2000 and May 2007 were enrolled in the study. Before TACE was carried out, MELD, MELD-Na, Child-Pugh score, Okuda stage, CLIP score, JIS score, BCLC stage, and UICC stage were checked. After one month, δMELD and δMELD-Na were calculated. Results. Mean MELD/MELD-Na/δMELD/δMELD-Na scores were 7.5±3.7, 8.0±4.7, -0.2±3.5 and 0.04±4.5, respectively. MELD (p=0.009) and MELD-Na (p=0.017) significantly correlated with survival, but δMELD and δMELD-Na did not (p >0.05). The Child-Pugh score and other staging systems correlated significantly with survival (p <0.05). The AUROC values for 3, 12, and 36 months' survival were 0.633, 0.545, and 0.615 for MELD; 0.655, 0.555, and 0.612 for MELD-Na; 0.639, 0.616, and 0.691 for Child-Pugh score; 0.714, 0.662, and 0.717 for the Okuda score; 0.837, 0.86, and 0.792 for the CLIP score; 0.859, 0.814, and 0.808 for the JIS score; 0.846, 0.833, and 0.749 for BCLC stage; and 0.878, 0.812, and 0.735 for UICC stage, respectively. Conclusions. MELD and MELD-Na showed good correlations with survival, especially for patients with early-stage disease. However, these were not superior to those of other staging systems or Child-Pugh score. These parameters should only be used as supportive data.
AB - Objective. The aim of this study was to evaluate the prognostic value of the model for end-stage liver disease (MELD) and its modified forms, and to compare these scoring systems with other staging systems for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). Material and methods. A total of 325 patients who underwent TACE for the initial treatment of HCC between January 2000 and May 2007 were enrolled in the study. Before TACE was carried out, MELD, MELD-Na, Child-Pugh score, Okuda stage, CLIP score, JIS score, BCLC stage, and UICC stage were checked. After one month, δMELD and δMELD-Na were calculated. Results. Mean MELD/MELD-Na/δMELD/δMELD-Na scores were 7.5±3.7, 8.0±4.7, -0.2±3.5 and 0.04±4.5, respectively. MELD (p=0.009) and MELD-Na (p=0.017) significantly correlated with survival, but δMELD and δMELD-Na did not (p >0.05). The Child-Pugh score and other staging systems correlated significantly with survival (p <0.05). The AUROC values for 3, 12, and 36 months' survival were 0.633, 0.545, and 0.615 for MELD; 0.655, 0.555, and 0.612 for MELD-Na; 0.639, 0.616, and 0.691 for Child-Pugh score; 0.714, 0.662, and 0.717 for the Okuda score; 0.837, 0.86, and 0.792 for the CLIP score; 0.859, 0.814, and 0.808 for the JIS score; 0.846, 0.833, and 0.749 for BCLC stage; and 0.878, 0.812, and 0.735 for UICC stage, respectively. Conclusions. MELD and MELD-Na showed good correlations with survival, especially for patients with early-stage disease. However, these were not superior to those of other staging systems or Child-Pugh score. These parameters should only be used as supportive data.
KW - HCC
KW - MELD
KW - Survival rate
KW - TACE
UR - http://www.scopus.com/inward/record.url?scp=61649086979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61649086979&partnerID=8YFLogxK
U2 - 10.1080/00365520802530838
DO - 10.1080/00365520802530838
M3 - Article
C2 - 18991165
AN - SCOPUS:61649086979
VL - 44
SP - 346
EP - 357
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 3
ER -